
Clinical-stage #biotech company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin.
Joined December 2020
- Tweets331
- Following40
- Followers613
- Likes30
Our CEO Pete Smith recently joined The Bio Report to discuss the science behind REM-422, progress in MYB-driven cancers, and the potential of RNA processing to expand the possibilities of precision medicine.
#RemixTherapeutics #PrecisionMedicine
Can altering RNA processing reach undruggable cancer targets? Remix Therapeutics CEO Peter Smith on the company’s experimental oral drugs that hit MYB, an elusive cancer target. thebioreport.podbean.com/e/m…
109
Following the FDA’s Rare Disease Framework Initiative Public Meeting, our CEO Pete Smith shares why scientific rigor and collaboration are essential to advancing new treatment options for rare disease communities.
Read more: bit.ly/3W7X4Hu
87
REM-422 will be featured in a late-breaking oral presentation at #ENA2026, highlighting updated interim Phase 1/2 ARIA data in ACC. We look forward to sharing the latest findings on our potentially first-in-class oral MYB mRNA degrader.
bit.ly/47JImZK
#Oncology #ACC
Welcome Michael Landsittel to the Remix BoD!
Michael brings 20+ years of biotech leadership experience, most recently as CFO of Blueprint Medicines. We're excited to benefit from Michael's expertise as we advance RNA-targeted medicines for patients.
Learn more: bit.ly/4j1sYPf
100
At #DrugDiscoveryOnTarget, our CSO, Dominic Reynolds, will highlight REM-422, our first-in-class mRNA degrader targeting the MYB oncogene, and discuss how our REMaster® platform is enabling new approaches to previously undruggable RNA targets.
#RNATherapeutics #DrugDiscovery
113
Please join us in welcoming Tony Mullin as our new Chief People Officer.
Tony has led people strategies at Omega Therapeutics, Pandion Therapeutics and Biogen, creating cultures that support innovation, growth and impact.
We're thrilled to have him on #TeamRemix.
1
122
We're excited to welcome Nicole Sweeny as Chief Commercial Officer! Nicole brings 20+ years of commercial leadership experience across specialty biopharma and rare disease, strengthening our efforts as we prepare for future growth.
Read more: bit.ly/4xMfafS
#TeamRemix
Thank you to everyone who joined us at the 21st Annual Wells Fargo Healthcare Conference. We were pleased to share updates on Remix's RNA-targeted therapeutics platform and pipeline and look forward to continuing the conversation.
#RemixTherapeutics #Biotech #RNATherapeutics
1
150
Join us this September at the Wells Fargo Healthcare Conference and Cantor Global Healthcare Conference.
We're excited to share updates on our progress and connect with investors and peers.
Read the press release: bit.ly/3Uk3IcO
#RemixTherapeutics #Biotech
🤖 Made with AI
2
148
CEO and co-founder Peter Smith joined @BiotechTV to discuss REM-422, our recent #ASCO26 data, and how Remix is working` to reprogram RNA processing to unlock a new class of medicines.
Thanks to @BradLoncar and the BiotechTV team for having us.
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: @RemixThera announced earlier this summer plans to go public via a reverse merger - it's on the back of clinical data that was presented for its RNA modulator at #ASCO26.
Full video: biotechtv.com/post/remix-the…
206
Hear from our CEO Pete Smith, at the Advances in Cancer Therapeutics symposium on Aug. 20. Pete will present on REM-422 in ACC and discuss emerging innovations in oncology.
Register: bit.ly/3Uxq6PI
#CancerResearch #Oncology #RemixTherapeutics #ACC
Stepping away from the day-to-day to celebrate the people behind our progress.
We're grateful for the dedication, creativity, and teamwork that drive Remix forward every day.
Thank you to the entire Remix Therapeutics team for helping us reach important milestones and advance our mission.
Here's to what we've accomplished together and what's ahead.
#TeamRemix #Biotech #LifeAtRemix
1
313
We look forward to connecting with the investor community at the 46th Annual Canaccord Genuity Growth Conference, where our Co-Founder and CEO, Pete Smith, will present a corporate overview.
Learn more: bit.ly/4fQtKv8
#Biotech #RNA #Oncology
2
212
Please join us in welcoming Gabe Fox, Senior Manager, Business Development, to Team Remix! Gabe’s expertise will help drive our next phase of growth as we advance our RNA-targeted therapeutics platform and pipeline. Welcome, Gabe! #TeamRemix #RNA #Oncology
🤖 Made with AI
2
145
Looking forward to sharing REM-422 progress at AACR Drug Discovery & Development. CEO Peter Smith will highlight the ongoing Phase 1/2 ARIA study in ACC and the potential of RNA processing therapeutics in MYB-driven cancers. bit.ly/4fdNOr6
#AACR #RNAtherapeutics
1
163
ICYMI: Endpoints News spoke with our CEO and Co-Founder, Peter Smith, about our recently announced merger agreement with Passage Bio and what’s ahead for our lead mRNA degrader REM-422.
Read more: bit.ly/4f5YNmc
#Biotech #Oncology #mRNADegraders #RemixTherapeutics
158
Today we announced a merger with Passage Bio, advancing our mission to reprogram RNA
processing and unlock a new class of medicines. Together, we aim to accelerate a pipeline of
small molecule therapies led by REM-422.
➡️Read more: bit.ly/4f31HJC
#Biotech
This #NationalCancer SurvivorsMonth, we join with the community to celebrate survivors and reaffirm our commitment to bringing better therapies to patients who have not seen significant therapeutic advancements and meaningfully improve outcomes for patients and their families.
71
Exciting day at #ASCO2026 yesterday as Dr. Renata Ferrarotto from UT MD Anderson Cancer Center presented data from the Phase 1/2 ARIA study of first-in-class MYB mRNA degrader, REM-422, in patients with R/M ACC.
bit.ly/4dpGN6Y
#REM422
Today we announced positive results from the ongoing Phase 1/2 ARIA clinical trial evaluating REM-422, a first-in-class MYB mRNA degrader, in patients with R/M ACC The data will be featured in an oral presentation at #ASCO2026.
Read the press release: bit.ly/4dpGN6Y

















